Slide 1: First Quarter Fiscal Year 2014 Conference Call and Webinar
Simulations Plus, Inc. (NASDAQ:SLP) First Quarter Fiscal Year 2014 Conference Call and Webinar January 9, 2014
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to su
Slide 3: SLP 1QFY14 Highlights
• 1QFY14 compared to 1QFY13: – Sales up 15.3% to First Quarter Record $2.64 million from $2.29 million – Gross profit up 15.2% to $2.193 million from $1.903 million – SG&A increased 15.0% to $1.071 million from $0.931 million • As a percent of revenues, SG&A decreased slightly to 40.6% from 40.7% –
Slide 4: Income Statement 1QFY14 vs 1QFY13
Income Statement 1QFY14 vs 1QFY13 ($ millions) 1QFY14 1QFY13 Net sales 2.641 2.290 Gross profit 2.193 1.903 Gross profit margin 83.0% 83.1% SG&A 1.071 0.931 R&D 0.162 0.180 Total operating expenses 1.233 1.111 Income from operations 0.959 0.792 Other income 0.033 0.104 Income from operations before
Slide 5: Revenues by Quarter
Revenues by Quarter (pro forma prior to 2012) $1.4 $1.8 $2.0 $1.1 $1.7 $2.2 $2.3 $1.3 $2.1 $2.6 $2.6 $1.4 $2.2 $2.8 $2.8 $1.6 $2.3 $3.1 $3.1 $1.6 2.64 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013 2014
Slide 6: Gross Profit by Fiscal Quarter
$1.24 $1.53 $1.75 $0.71 $1.45 $1.93 $1.97 $1.07 $1.70 $2.21 $2.21 $1.12 $1.90 $2.39 $2.33 $1.32 $1.90 $2.62 $2.64 $1.26 $2.19 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013 2014 Gross Profit by Fiscal Quarter (pro forma prior to 2012)
Slide 7: EBITDA by Fiscal Quarter
$0.55 $0.73 $0.93 $0.20 $0.73 $1.28 $1.23 $0.36 $1.00 $1.48 $1.48 $0.27 $1.23 $1.38 $1.48 $0.58 $1.09 $1.76 $1.73 $0.44 $1.20 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013 2014 EBITDA by Fiscal Quarter
Slide 8: Net Income by Quarter
Net Income by Quarter (pro forma prior to 2012) $0.33 $0.47 $0.53 $0.17 $0.44 $0.85 $0.74 $0.21 $0.56 $0.91 $1.05 $0.17 $0.76 $0.84 $0.87 $0.35 $0.59 $1.06 $0.99 $0.24 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013 2014
Slide 9: New Customers by Quarter
10 11 9 9 14 17 12 14 15 21 13 10 18 18 16 9 15 Q1 Q2 Q3 Q4 2010 2011 2012 2013 2014 New Customers by Quarter
Slide 10: Selected Balance Sheet Items
Selected Balance Sheet Items ($ millions) November 30, 2013 August 31, 2013 Cash and cash equivalents $10.555 $10.179 Cash per fully diluted share 0.64 0.62 Total current assets 13.136 12.972 Total assets 16.405 16.063 Total current liabilities 0.791 0.626 Total liabilities 2.054 1.821 Current ratio
Slide 11: Returning Cash to Shareholders
$1.59 $0.80 $0.80 $2.24 $0.00 $0.48 $0.48 $0.64 $1.97 $12.66 $13.24 $12.89 $12.70 $11.38 $9.33 $9.76 $10.00 $10.18 $10.56 Q4FY11 Q1FY12 Q2FY12 Q3FY12 Q4FY12 Q1FY13 Q2FY13 Q3FY13 Q4FY13 Q1FY14 $ Millions Dividend Paid Proceeds from Sale of Subsidiary Cash Returning Cash to Shareholders
Slide 12: Simulations Plus Products & Services
N H O OH O CH 3 CH 3 CH 3 Discovery Preclinical Clinical MedChem Studio™ MedChem Designer™ GastroPlus™ DDDPlus™ ADMET Predictor™ Simulations Plus Products & Services Consulting Services & Collaborations MembranePlus ™
Slide 13: Product News
Product News • Version 8.5 released Q4FY2013 • Unique precipitation model added • Infant PBPK physiologies added – pediatrics is high - interest area in FDA and industry • Added a built - in method for transporter in vitro - in vivo extrapolation • Added a number of additional built - in enzyme expr
Slide 14: Marketing and Sales Program
Marketing and Sales Program • Conferences /Scientific Meetings continue to be primary source of leads • During Q1 we participated in 13 scientific meetings and conferences in the U.S . and Europe with 13 scientific posters and presentations • Trainings and Workshops • Conducted 7 on - site training
Slide 15: NCE (New Chemical Entity) Project
NCE (New Chemical Entity) Project • New NCE project initiated , molecules synthesis just completed • Selection of contractor for experiments is imminent – results expected by March 1 • COX - 2 selected as target (Celebrex® target) • COX - 1 also needs to be inhibited, but at a lesser level (Aspirin
Slide 16: Growth Opportunities
Growth Opportunities • MembranePlus™ - new software product to simulate in vitro permeability experiments • similar concept to DDDPlus ™ - unique capability in the industry • Continued enhancement of current software products to expand coverage into new areas • Dermal dosing module in GastroPlus ™ •
Slide 17: Summary
Summary • For 1QFY14: - Record revenues and earnings = continued 6 - year - plus profitable trend - Earnings growth 16.7% on 15.3% revenue growth • Continuing to Grow: - Three new Ph.D.s added in FY13 - Continuing to seek and interview additional scientists and engineers - Life Sciences team strengt
Slide 18: Simulations Plus, Inc.
simulationsplus, inc, é